Cystic Fibrosis (CF) Therapeutics Market is expected to be valued at USD 13.9 billion with CAGR of 16.7% over the forecast period. Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs, digestive systems and other organs in the body. In this state, CF affects the cells that are responsible for sweat, mucus digestive and fluid juices. These juices are normally thin and slippery but patients suffering from cystic fibrosis experience thick blockage in lungs and other organs, as this affects the cells that regulate digestive and fluid juices causing them to become an obstacle rather than carriers. The cells instead of acting as a lubricant become sticky and thick, thus blocking up lungs, pancreas and other organs in the body. Medically this disease is termed as mucoviscidosis.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market/request-sample
The key driving factors responsible for the growth of Cystic
Fibrosis (CF) Therapeutics market :
The major driving factors of this
market rely significantly on extensive R&D. As the ongoing R&D
activities have boosted the CF therapeutics market and witnesses a lucrative
growth in the upcoming years. The other driving factors like awareness for
cystic fibrosis therapy, technological advancements in R&D attribute to the
success of market growth. However, high costs of treatment and R&D,
entangled pathophysiology, rising rate in genetic mutation are some factors
that may cause to hinder the market growth. On the basis of therapeutics, the
global market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace,
Aeroquin and others.
Cystic Fibrosis Trans membrane
Conductance Regulators (CFTR) modulators treat the root cause of disease rather
than symptoms, resulting in improving the lives of patients. Kalydeco is the
first CFTR modulator to enter the market and had a large impact on the value of
market though it treated a small proportion of CF patients. Pricing will be
premium for CFTR modulators due to the therapeutic benefits. Symptomatic
therapies will continue to be a necessary part in conjunction with CFTR
modules. Comparatively, the antibiotics segment is expected to gain second
importance owing to the competitiveness and novel market entrants.
A multi-resistant superbug
infection that can prove fatal for patients suffering from cystic fibrosis (CF)
has spread globally and is becoming viral, according to the British
researchers. Moreover, it has not only gone viral but is evolved and capable to
jump from patient to patient, according Andres Floto, a Cambridge University professor.
Adding further, he said that as the superbug has become resistant to various
antibiotics; it is also difficult to treat it successfully. As a part of
treatment infected patients may need more than a year of treatment with a
combination of strong antibiotics and the ratio of cure is one in three.
The market is segmented on the
basis of geography which includes North America, Europe, Asia-Pacific,
Middle-east and Africa. The European region dominates the global market
scenario and is considered as the most fertile market which is also followed by
North America. Asia-pacific regions are considered to be the least important
market owing to less prevalence of the disorder. The key players include
Novartis International AG, Chiesi Farmaceutici SpA, Vertex Pharmaceuticals,
Genentech, Inc., and Gilead Sciences, Inc. Vertex Pharmaceuticals is the
developer of kalydeco and expected to be a key player in the global market.
View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market
No comments:
Post a Comment